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prevention. RESULTS: The expected number of avoided AD cases by selecting PHF-W 
over CMF was 2,787 cases in a birth cohort of 38,661 at risk infants. The base-case 
analyses generated expected ICERs of c1921, -c1102 (savings) and c785 from the 
MOH, family and SOC perspectives, respectively. Cost drivers were formula from the 
MOH perspectives and time loss from the family perspective, with formula and to a 
lesser extent time loss for the SOC perspective. PHF-W yielded approximately c10.7 
million savings against EHF in the secondary analysis. One-way and probabilistic 
sensitivity analyses conﬁ rmed the robustness of the model. CONCLUSIONS: Under 
a range of assumptions, this analysis has established the cost-effectiveness of PHF-W 
in the prevention of AD among Spanish infants.
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OBJECTIVES: Bevacizumab (Avastin) is a promising and low cost treatment of age-
related macular degeneration. Effectiveness and cost-effectiveness might be related to 
the frequency of injections of bevacizumab in the treatment. The standard frequency 
is 4 weeks, while it is uncertain whether lower frequencies lead to different cost and 
effects. METHODS: 170 patients were randomized to 3 treatment frequencies; 4, 6, 
and 8 week intervals between injections. Follow up was 1 year. Vision was measured 
with the Snellen chart, which health states have been valued for QALY analysis. We 
developed a 6 states Markov model with a 12 weeks cycle and a 6-year time-horizon. 
The model included one death state, and ﬁ ve states deﬁ ned by visual acuity(VA) in 
the better seeing eye: VA >20/40, ≤20/40 to >20/80, ≤20/80 to >20/200, ≤20/200 to 
>20/400 and ≤20/400. RESULTS: At time of the (interim) analyses, 72 patients had 
completed the full follow up. The ‘6 weeks’ frequency compared with ‘4 weeks’ shows 
a negative ICER of c6.406, with c1,024 less costs and 0.16 more QALY’s. The ‘8 
weeks’ frequency compared to the 4 weeks frequency shows also a negative ICER of 
c28,032, with c1.543 less costs and 0,06 more QALY’s. When looking at 6 and 8 
weeks, the ‘8 weeks’ has lower costs but is also less effective, with an ICER of c4.946. 
Most uncertainty related to utilities and transition probabilities, while cost contributes 
relatively less to the uncertainty of the outcomes. CONCLUSIONS: Compared with 
4 weeks frequency, the 6 and 8 weeks frequency were dominant, whereas the 8 weeks 
frequency has an ICER in the south west quadrant.
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OBJECTIVES: To assess whether evidence-based cost-utility of PRN-dosing with 
ranibizumab (Lucentis®, RBZ-PRN) in age-related macular degeneration (AMD) is 
comparable to RBZ-PRN cost-utility estimated previously based on clinical data from 
monthly and quarterly regimens. METHODS: A 10-year MS-Excel Markov model 
with 5 visual acuity (VA) levels and 1 death state predicts VA in patients treated with 
RBZ-PRN, RBZ quarterly (RBZ-Q), RBZ monthly (RBZ-M), Visudyne® photody-
namic therapy (PDT) or best supportive care (BSC). Transition probabilities, adverse 
events and treatment frequencies were provided by newly available PRN-trials 
(SUSTAIN, MONT BLANC) + available trials covering other comparators (ANCHOR, 
MARINA, PIER, EXCITE, TAP). Comparability of populations and treatment effects 
(linear regressions) determined trial data pooling. Final analyses included pooled data 
sets (RBZ-PRN and RBZ-Q) or multiple single-trial data sets (other comparators). 
Secondary analysis included indirect comparison versus pegaptanib sodium (PGB). 
Two-year treatment duration was followed by BSC. Costs (2009, UK health care 
payer, 3.5% discount) were obtained from literature and expert opinion; utilities 
(3.5% discount) from a time-trade-off study. One-way and probabilistic sensitivity 
analyses (SA) covered variability in efﬁ cacy, costs, treatment frequency and utilities. 
RESULTS: Due to lower than predicted injection frequency, clinical trial-based cost-
utility of RBZ-PRN was better than predicted cost-utility. Evidence-based cost-utility 
ranged from £4,414/QALY to £20,489/QALY versus BSC and from dominance to 
£2,383/QALY versus PDT. RBZ-PRN was dominant versus RBZ-Q and versus PGB 
(secondary indirect analysis). RBZ-M was slightly more effective but not cost-effective 
versus RBZ-PRN. The result was most sensitive to time horizon (2–10 y), cost of 
blindness and treatment duration (1–3 y) but conclusions remained throughout 1-way 
SA. Assuming a threshold of £30,000/QALY, the probability that RBZ-PRN is cost-
effective ranged from 68% to 97% versus different comparators. CONCLUSIONS: 
RBZ-PRN using the SUSTAIN and MONT-BLANC re-treatment criteria is cost-
effective compared to other therapies for wet-AMD and represents the most cost-
effective use of RBZ.
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OBJECTIVES: The objective of this study was to determine the cost-effectiveness of 
tacrolimus ointment used twice weekly as a maintenance treatment regimen compared 
to a standard treatment regimen using tacrolimus twice daily in both adults and 
children with moderate to severe atopic dermatitis (AD) in Norway and Finland. 
METHODS: A decision analytic approach was used to compare costs and outcomes 
of two alternative management strategies for AD over a 12 month treatment period 
for the UK, which was adapted for Norway and Finland. Efﬁ cacy data were used from 
two randomised controlled trials where maintenance use of tacrolimus ointment 
(0.1% in adults and 0.03% in children applied twice weekly) was applied to previously 
affected areas compared to standard use (twice daily application) to treat disease 
exacerbations. Utility data were derived from a published source and cost data were 
taken from public list prices and tariffs in the two countries, Norway and Finland to 
generate cost/QALY. Sensitivity analyses were performed to test the degree of uncer-
tainty around the results. RESULTS: The twice weekly maintenance use of tacrolimus 
ointment resulted in fewer days in disease ﬂ are and improved quality of life versus 
standard treatment with tacrolimus ointment in both adults and children with moder-
ate to severe AD. The twice weekly regimen was cost-saving compared with the 
standard regimen in both Norway and Finland. Sensitivity analyses demonstrated that 
results were largely insensitive to change. CONCLUSIONS: Twice weekly mainte-
nance treatment of moderate and severe AD in both adults and children using tacro-
limus ointment improves health outcomes at a lower cost when compared with the 
reactive treatment strategy using tacrolimus ointment.
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Indirect costs are not only generated by sick people themselves, but often occur due 
to sick children needing informal care by parents or other informal care givers. Infor-
mal care givers are relatives or friends, not being paid for their services and thereby 
experiencing work, leisure time and productivity loss. Indirect costs induced by infor-
mal care givers are rarely included in CEA, although being part of societal cost. 
OBJECTIVES: This study quantiﬁ ed the indirect costs of an informal care giver caused 
by a sick child suffering from an episode of acute otitis media (AOM) in Germany. 
METHODS: Using a German access panel questionnaires were sent out to households 
with children <5years. The following indirect costs referring to the most recent AOM 
episode of any child were covered: hours of work absence and related costs for 
mothers, fathers and grandparents; loss of leisure time; productivity loss caused by 
solicitousness; work loss compensation by colleagues. RESULTS: A total of 68.3% of 
all parents experienced 7–29 hours of work loss (59.3/9.3% mothers/fathers) per 
episode, grandparents 14 hours (2%). While 40% of parents experienced paid and 
28% unpaid work loss, grandparents being retired caused only unpaid productivity 
losses. Leisure time loss was experienced by all informal caregivers and an average 
was calculated across the total population accounting for c47.39. Indirect costs per 
AOM episode across the total population were in average c411.40 (Sum of: c152.51 
paid, c161.89 unpaid work loss, c209.07 productivity, c47.39 leisure time loss; 
Subtraction of: c45.72 paid, c113.74 unpaid work compensation by a colleague). 
CONCLUSIONS: Indirect costs are mainly included in health economic (HE) analyses 
as paid work loss. For Germany paid work loss only accounted for 38% of total 
indirect costs referring to an AOM episode. Further detailed studies are needed to 
better understand the inﬂ uence of different indirect cost categories across disease areas. 
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OBJECTIVES: To measure the inﬂ uence of introducing guidelines to doctors and 
educational leaﬂ ets to patients on reducing the level of prescribed antibiotics. To 
investigate the effect of factors such as socio-demographic characteristics, signs, symp-
toms and patient self management. METHODS: Research was conducted in two busy 
clinics, one in Dubai and one in Sharjah. a set of guidelines for the treatment of sore 
throat were extracted from the SIGN guidelines (Appendix 3). The set of guidelines 
was explained to the General Practitioners individually. The guidelines were accom-
panied by a covering paper which explained why and where the guidelines were 
produced. The researcher was based in the nursing room and approached patients 
suffering from a sore throat. These patients were given the educational leaﬂ et and a 
brief explanation of what the leaﬂ et included. The length of explanation depended on 
whether the patient could read or not. They were then asked a set of questions prior 
